Connect with us

Life Sciences

NAMSA Transforms Integrated MedTech Commercialization Solution: The NAMSA APEX Program

NAMSA announced today the transformation of its integrated MedTech commercialization solution: the NAMSA APEX Program. NAMSA’s strategic outsourcing…

Published

on

This article was originally published by NAMSA

TOLEDO, OHIO—BUSINSESWIRE—NOVEMBER 17, 2022—NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today the transformation of its integrated MedTech commercialization solution: the NAMSA APEX Program™. The relaunch and transformation of the Program reflects NAMSA’s continued focus on strategic outsourcing solutions to address development challenges encountered by MedTech Sponsors, resultant from current market conditions and demands.

NAMSA’s strategic outsourcing solution, the NAMSA APEX Program (Assess, Plan, Execute), is introduced at a time when the MedTech industry is experiencing changing regulatory requirements and expanding clinical evidence demands. Sponsors are facing longer development timelines, putting them at risk for increased costs and lagged speed-to-market—often the key drivers of MedTech success. Helping Sponsors plan for these challenges is the NAMSA APEX Program: an approach that delivers integrated services and tools that provide predictable planning, phase overlap and immediate access to top Subject Matter Experts in Clients’ therapeutic, geographic and regulatory focus areas. This ultimately allows Sponsors to proactively mitigate risk, preserve capital and create stakeholder alignment to accelerate commercialization.

Commenting on the strategic outsourcing solution is Tim Mitchell, NAMSA Vice President of Strategic Programs, “In today’s value-based environment, the commercial challenges are more numerous than ever as regulatory approval does not guarantee market adoption. This has placed increased demand on MedTech Sponsors to find trusted outsourcing partners to accelerate efficient clinical development of innovative medical products.” Mitchell continued, “NAMSA’s APEX Program is one approach to help ensure an efficient path to commercial success. As a result of our work with more than 100 APEX Program Clients, we understand how to set the stage for efficient product approval and market adoption through our established regulatory partnerships and utilization of only the most proven development strategies.”


MedTech developers wishing to learn more about the NAMSA APEX Program and other strategic outsourcing solutions are invited to sign-up for a complimentary consultation via the company’s website at: www.namsa.com/services/apex-program/.

The post NAMSA Transforms Integrated MedTech Commercialization Solution: The NAMSA APEX Program first appeared on NAMSA.

contract research
cro
medical

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending